Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
| Property | GHK-Cu | BPC-157 |
|---|---|---|
| Class | Cosmetic / reparative peptide | Cytoprotective peptide |
| Research category | dermatology and wound-healing models | tissue repair and gastrointestinal models |
| Evidence level | Low–moderate | Low |
| Overall status | Cosmetic ingredient — not approved as a drug | Not approved — research |
| FDA | Cosmetic ingredient; not approved as a drug | Not approved |
| EMA | Not approved as a medicine | Not approved |
| WADA | Check current list | Prohibited — S0 (check current list) |
| Mechanism studied | GHK-Cu → Dermis → Collagen & ECM → Matrix remodelling | BPC-157 → Fibroblasts & endothelium → VEGFR2 / NO signalling → Tissue remodelling |
| Molecular weight | 400.9 g/mol | 1,419.5 g/mol |
| Sizes in stock | 50mg, 100mg | 5mg, 10mg |
Where the research overlaps
Both compounds are studied within Tissue Repair research. GHK-Cu is classed as cosmetic / reparative peptide, while BPC-157 is cytoprotective peptide. Evidence is rated low–moderate for GHK-Cu and low for BPC-157.
For a full write-up, read Peptide Stability and Degradation Pathways Explained.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.